Theranos’ Epic Self-Destruction Offers Lessons for Biotech Companies
Whistleblowers Erika Cheung and Tyler Shultz discussed their experiences at Theranos during the recent 2022 AACC Annual Scientific Meeting & Clinical Lab Expo.
168澳洲8官网历史查询-澳洲幸运8开奖号码走势图|手机版澳洲幸运8开奖结果 The Home of the Life Sciences Industry
With $122M, Startup IDRx Intends to Stop Cancer Mutations in their Tracks
IDRx aims to create highly selective and aligned drug combinations to stop key tumor escape mechanisms that will support prolonged and durable responses to therapy.
More Top Stories
- AAIC: Amyloid-Beta Oligomers, an Intranasal Antibody and a Vaccine ...
- As Psychedelic Therapies Advance, Regulators Must Weigh Results aga...
- In New Direction, Allarity Deems Risk of Monotherapies too High
- FDA Presses Play on Celyad and Pause on Beam for Cancer Candidates
- Priority Review of Gamida’s Novel Transplant Therapy Reflects Urgen...
